NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNERCID is a streptogramin antibiotic combination (quinupristin/dalfopristin) administered intravenously to treat serious gram-positive bacterial infections, including vancomycin-resistant Enterococcus faecium (VREF). The drug works by inhibiting bacterial protein synthesis through dual mechanisms targeting the bacterial ribosome.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a consolidating team focused on transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
Started Jun 2000
Gram-Positive Bacterial Infections
Career Relevance
Working on SYNERCID offers limited career growth opportunity due to its LOE-approaching lifecycle stage and minimal linked job openings. This role is best suited for professionals seeking to manage mature product transitions, optimize hospital formulary positioning, or gain experience in specialist infectious disease marketing before transitioning to growth-stage assets.
Brand Manager
Worked on SYNERCID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.